Enzalutamide-Induced Signatures Revealed by Epigenetic Plasticity Using Single-Cell Multi-Omics Sequencing in Prostate Cancer

Authors

Huihui Fan
Jinze Li
Astrid M Manuel
Zhongming Zhao

Publication Date

3-14-2023

Journal

Molecular Therapy Nucleic Acids

Abstract

Prostate cancer is morphologically and molecularly heterogeneous, which poses obstacles for early diagnosis and treatment. Advancements in understanding the heterogeneity of prostate cancer will help navigate through these challenges and ultimately benefit patients. In this study, we integrated single-cell sequencing for transposase-accessible chromatin and whole transcriptome in prostate cancer cell lines, aiming to decode the epigenetic plasticity upon enzalutamide (ENZ) treatment. By comparing the cell populations representing early-treatment response or resistance to the initial tumor cells, we identified seven signature gene sets; they present consistent trends of chromatin closing co-occurred with down-regulated genes during early response and chromatin opening with up-regulated genes upon maintaining drug resistance. In the molecular signatures, we found genes

Keywords

MT: Bioinformatics, single-cell RNA sequencing, single-cell ATAC sequencing, prostate cancer, enzalutamide treatment, combinatory drug candidates, tumor prognosis

Comments

Supplementary Materials

PMID: 36910711